High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma
Authors
Keywords
-
Journal
Science Advances
Volume 6, Issue 25, Pages eaba5542
Publisher
American Association for the Advancement of Science (AAAS)
Online
2020-06-18
DOI
10.1126/sciadv.aba5542
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer
- (2019) Jatin Sharma et al. Frontiers in Pharmacology
- Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response
- (2019) Fulvia Vascotto et al. OncoImmunology
- Adaptation and memory in immune responses
- (2019) Gioacchino Natoli et al. NATURE IMMUNOLOGY
- Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
- (2019) Amy L. Shergold et al. PHARMACOLOGICAL RESEARCH
- VE-822 mediated inhibition of ATR signaling sensitizes chondrosarcoma to cisplatin via reversion of the DNA damage response
- (2019) Xiao Liang et al. OncoTargets and Therapy
- Drug Combination Synergy in Worm-like Polymeric Micelles Improves Treatment Outcome for Small Cell and Non-Small Cell Lung Cancer
- (2018) Xiaomeng Wan et al. ACS Nano
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
- (2018) Limo Chen et al. Cancer Discovery
- TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
- (2018) Christopher B. Rodell et al. Nature Biomedical Engineering
- What, Why, Where, and When: Bringing Timing to Immuno-Oncology
- (2018) Adrienne M. Rothschilds et al. TRENDS IN IMMUNOLOGY
- Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: Implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments
- (2018) Xiaomeng Wan et al. BIOMATERIALS
- Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhighneutrophils
- (2017) Camilla Engblom et al. SCIENCE
- Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system
- (2017) Liang Cheng et al. VACCINE
- Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer
- (2017) Jane Cullis et al. Cancer Immunology Research
- A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity
- (2016) Zhijian He et al. BIOMATERIALS
- Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery
- (2016) Stéphane Renaud et al. BRITISH JOURNAL OF CANCER
- Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
- (2016) KM Morrissey et al. CTS-Clinical and Translational Science
- Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles
- (2016) Antonio Rossi et al. Expert Review of Anticancer Therapy
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- Regulation of the IL-10-driven macrophage phenotype under incoherent stimuli
- (2016) Yishan Chuang et al. Innate Immunity
- PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?
- (2016) Yusuke Inoue et al. Translational Cancer Research
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Tumor-associated macrophages in cancers
- (2015) W. Hu et al. Clinical & Translational Oncology
- Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors
- (2015) Sebastian Schölch et al. Oncotarget
- Tumor-associated macrophages: Co-conspirators and orchestrators of immune suppression in endometrial adenocarcinoma
- (2014) Emese Zsiros et al. GYNECOLOGIC ONCOLOGY
- Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs
- (2014) C. V. Pecot et al. MOLECULAR CANCER THERAPEUTICS
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
- (2014) Limo Chen et al. Nature Communications
- Liposomal resiquimod for the treatment of Leishmania donovani infection
- (2013) K. J. Peine et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Nanotoxicity comparison of four amphiphilic polymeric micelles with similar hydrophilic or hydrophobic structure
- (2013) Bo Zhao et al. Particle and Fibre Toxicology
- Tumour angiogenesis regulation by the miR-200 family
- (2013) Chad V. Pecot et al. Nature Communications
- Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma
- (2012) S. J. Dovedi et al. BLOOD
- The mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like receptor triggering
- (2012) Harpreet Singh-Jasuja et al. IMMUNOBIOLOGY
- The pro- and anti-inflammatory properties of the cytokine interleukin-6
- (2011) Jürgen Scheller et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Molecular mechanisms of cisplatin resistance
- (2011) L Galluzzi et al. ONCOGENE
- The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system
- (2011) Abbi L Engel et al. Expert Review of Clinical Pharmacology
- Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs
- (2010) Robert Luxenhofer et al. BIOMATERIALS
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Monoclonal antibody-induced cytokine-release syndrome
- (2009) Peter J Bugelski et al. Expert Review of Clinical Immunology
- AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
- (2008) S. D. Zabludoff et al. MOLECULAR CANCER THERAPEUTICS
- The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy
- (2008) E. L. J. M. Smits et al. ONCOLOGIST
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started